作者: Evgeny Izumchenko , David Sidransky
DOI: 10.1158/2159-8290.CD-15-0336
关键词: Signal transducing adaptor protein 、 Lung 、 Mutation 、 Adenocarcinoma 、 Carcinogenesis 、 Immunology 、 Lung cancer 、 Genetically Engineered Mouse 、 Cancer research 、 Mutant 、 Biology
摘要: With multiple clinical trials under way targeting mutant EGFR in patients with lung cancer, Maity and colleagues address important aspects of a MIG6-EGFR signaling axis using genetically engineered mouse models expressing mutated EGFRs on the MIG6-deficient background. This study extends our understanding regulation by MIG6 reveals that antagonizes tumor formation EGFR-driven adenocarcinoma.